Home › Autoimmune Diseases › Texas
Autoimmune Diseases clinical trials in Texas
22 studies for Autoimmune Diseases are looking for participants at sites in Texas.
Cities in Texas
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
- Novel Research LLC, Bellaire
- Arthritis Care of Texas, Corpus Christi
- Precision Comprehensive Clinical Research Solutions, Euless
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07621809A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
- Jade Clinical Site, Houston
RecruitingPhase 2
Ages 18 to 60 · All sexes · Updated Sep 25, 2026 · NCT07541287Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
- and 2 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Baylor College of Medicine, Houston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06722235RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- University of Texas Southwestern Medical Center - Accepting Juvenile Patients, Dallas
- Houston Methodist Hospital - Accepting Adult Patients, Houston
- University of Texas MD Anderson Cancer Center - Accepting Adult Patients, Houston
RecruitingPhase 2/3
Ages 6 to 75 · All sexes · Updated Sep 17, 2026 · NCT06154252Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
- University of Texas - Houston, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07103746A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Baylor College of Medicine, Houston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06948318A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
- GSK Investigational Site, Houston
- GSK Investigational Site, Temple
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06572384RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 to 65 · All sexes · Updated Aug 26, 2026 · NCT06121297Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility Study
- University of Texas at Austin, Austin
Recruiting
Ages 18 to 80 · All sexes · Updated Aug 17, 2026 · NCT07759115Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
- Dallas Renal Group, Dallas
- Dallas Renal Group, Dallas
- Nephro Asso North Illinois Indiana, Houston
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Aug 17, 2026 · NCT06858319RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
- Baylor College of Medicine Neurology Department, Houston
- Houston Methodist Hospital, Houston
- University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Aug 13, 2026 · NCT06359041Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
- MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT06817889A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
- UT Southwestern Medical Center, Dallas
- Cook Children's Medical Center, Fort Worth
- Texas Children's Hospital/ Baylor College of Medicine, Houston
- and 1 more
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Aug 6, 2026 · NCT06056297Study of BHV-1300 in Graves' Disease
- Site-109, Dallas
- Site-106, Houston
- Site-101, Houston
- and 1 more
RecruitingPhase 1
Ages 18 to 65 · All sexes · Updated Jul 31, 2026 · NCT06980649Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1003, Dallas
- Site Number - 1047, Denton
- Site Number - 1057, Houston
- and 1 more
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Jul 30, 2026 · NCT07039916KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
- Houston Methodist Hospital, Houston
RecruitingPhase 2/3
Ages 18 to 75 · All sexes · Updated Jul 29, 2026 · NCT06193889A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Medical City Dallas, Dallas
- Children's Medical Center Dallas, Dallas
- Zachary & Elizabeth Fisher Bone Marrow Transplant Program (Brooke Army Medical Center), Fort Sam Houston
- and 5 more
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- UT Southwestern Medical Center, Dept. of Dermatology, Dallas
- MD Anderson Texas Medical Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated May 29, 2026 · NCT04422912Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
- M D Anderson Cancer Center, Houston
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 20, 2026 · NCT04751396Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
- MD Anderson Cancer Center, Houston
- The University of Texas Health Science Center at Houston, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 15, 2026 · NCT06434363A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
- UT Southwestern Medical Center, Dallas
- Houston Methodist Hospital, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 25, 2026 · NCT06626919From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.